All News

ACR Best

#ACR 2024 BEST Abstracts from Day 2

Jack Cush, MD

Here’s a collection of some of the best abstracts presented on day 2 of ACR 2024 as selected by the RheumNow faculty.

 

Read Article
Conv3.jpg

ACR 2024 - Day 2 Report

Jack Cush, MD

Plenary sessions began the day, followed by thousands on the abstract floor. Here are a few of my favorite presentations from day 2 at ACR 2024.

Read Article
bathroom scale

Shedding Weight and Pain: The Promise of Anti-Obesity Medications in RA

Caoilfhionn Marie Connolly, MD

With the advent of FDA-approved anti-obesity medications such as semaglutide and tirzepatide, a new avenue for managing this challenging patient population has emerged. But how might these drugs impact the trajectory of RA, and are we on the cusp of a paradigm shift?

Read Article
Risks for HCQ cardiotoxicity: 👉>5 yrs use 👉>5 mg/kg/d (cumulative dose >500,000 mg) 👉CKD 👉use NSAID 👉preexisting heart dz 👉presence of ocular, derm, SkM toxicity - Dr M Garschik #ACR24 @rheumnow https://t.co/LFobgls4jm

Links:

TheDaoIndex KDAO2011 ( View Tweet)

#2259 💊 Anti-Obesity Meds in RA 📊 152 RA patients on semaglutide/tirzepatide 🔑 Findings 💥Significant ⬇️weight, BMI, ESR, CRP, lipids, pain VAS 💥Improved CVD risk ⛔ 15% GI side effects, 27% discontinued 🔎Study of impact on RA outcomes needed #ACR24 @RheumNow #ACRBest https://t.co/6LCTZl5173

Links:

Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Dr. @karen_kc123 discusses the results of the VITAL study. - Long term use of Vit D3 2000IU was safe and decreased the incidence of all autoimmune dses by 22%. - It took a while to work but the effect dissipates once discontinued. @RheumNow #ACR24 @rheumarhyme https://t.co/mnwRsdZ06N

Links:

sheila RHEUMarampa ( View Tweet)
A#2532 Pre-existing AID for immunoRx? Excluded from trials 4 prior studies showed no diff in mortality w AID Propensity-matched cohort study Followed median 250 days Hazard ratio: 1.07 (unmatched), 0.97 (matched) - no diff. Mortality about 40% in grps @RheumNow #ACR24 https://t.co/zyVCPts6s6

Links:

Eric Dein ericdeinmd ( View Tweet)
Gottenberg et al. A positive RCT in pSS! DAHLIAS study. Phase 2. 163 patients. Nipocalimab, anti-neonatal Fc receptor (FcRn) mAb. @RheumNow #ACR24 Abstr#2527 https://t.co/M7li4ZoKeY https://t.co/gV9MGnswdR

Links:

Richard Conway RichardPAConway ( View Tweet)

A#2527 DAHLIAS, P2 Nipocalimab: Anti-FcRn Ab in Ro+ SjD IV 5 or 15 mg/kg Prim Endpt: 15 mg/kg has ClinESSDAI at w24 -6.4 v -3.7 PBO p=0.002 Improv dryness, fatigue, pain Better unstim salivary flow Best response in higher Ab titer pts Safety data good #ACRBest #ACR24 @RheumNow https://t.co/O7zahPul66

Links:

Eric Dein ericdeinmd ( View Tweet)
Fertility in RA. Improved outcomes in the T2T group. Abstr#1647 @RheumNow #ACR24 https://t.co/gLpY8enaEb

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Shifting Trends in Initial RA Treatment Approaches A recent study by Sparks et al (Abstract #0509) reveals evolving trends in disease-modifying antirheumatic drug (DMARD) usage for rheumatoid arthritis (RA) over two decades in the U.S. https://t.co/6FN0WayZZR #ACR24 https://t.co/dc3CiNpKmx

Links:

Dr. John Cush RheumNow ( View Tweet)
Nice data from the OTIS Autoimmune Disease in Pregnancy Project re: certolizumab-exposed pregnancies: - spontaneous loss rate comparable to non-disease controls - no stillbirths - preterm similar to disease controls Plenty positive for CZP in pregnancy! #ACR24 ABST0805 @RheumNow https://t.co/XCRYsioxC0

Links:

David Liew drdavidliew ( View Tweet)
A study exploring the benefits of treating RA patients to remission after achieving low disease activity (LDA). Key findings: - Among patients initially at LDA, achieving remission (CDAI ≤2.8) led to significantly better functional outcomes and reduced durable medical equipment… https://t.co/SNPKlRieur https://t.co/YIQNMf3Oap

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

Abst#1493 complete renal response (< 0.5 g/g w/< 10 mg/day pred); renal remission (UPCR < 0.3 g/g w/< 5 mg/day pred). 60 LN pts followed 3 yrs: 40% CRR & 19% RR. Pts not in CRR/RR had⬇️eGFR w/more decline in eGFR over time. No difference b/t CRR/ RR @rheumnow #ACRbest #ACR24

TheDaoIndex KDAO2011 ( View Tweet)

Steroids in checkpoint inhibitor rheumatic irAEs need to be approached with caution. Persistent higher doses earlier on might dampen ICI response. @HSpecialSurgery ICI-IA (inflamm arthritis) cohort big diff in survival based on early steroid exposure #ACR24 ABST1989 @RheumNow https://t.co/3WAZ3ZLbFw

Links:

David Liew drdavidliew ( View Tweet)
Rheumatic irAEs can get on the CAR-T bandwagon, too! CAR-T can invoke new rheumatological issues (not just cytokine release) - see @DrGomezPuerta's experience. Infrequent, but if CAR-T in general becomes common, yet another job for us to attend to... #ACR24 ABST2004 @RheumNow https://t.co/xBSlhUdkNr

Links:

David Liew drdavidliew ( View Tweet)
Now that nipocalimab is approved for Sjogren's Disease, what about vaccination response whilst on this FcRn inhibitor (inherently lowers IgG)? Actually, not bad: takes a little longer to get there, but reassuring! (always fun to get to know a new med) #ACR24 ABST1988 @RheumNow https://t.co/IYqIGo5xVP

Links:

David Liew drdavidliew ( View Tweet)
Post hoc analysis of SPIRIT H2H evaluated nail involvement as a measure of ttnt response in PsA. -Pts with nail involvement treated with IXE or ADA had higher SJC and TJC improvement vs those without involvement at W12, W24 and W52. -IXE achieved rapid response for DAPSA-LDA as… https://t.co/SR36qCthQo https://t.co/hI3tD5hATJ

Links:

Adela Castro AdelaCastro222 ( View Tweet)
The anti-MCTD group strikes back Of cohort of over 1,000 RNP+ pt, only 17 clinically diagnosed with MCTD Majority of patients, despite potential overlap, treated for other primary rheum dz @RheumNow #ACR24 https://t.co/vkQ6UPs34y

Links:

Brian Jaros, MD Dr_Brian_MD ( View Tweet)
In this systematic review & metaanalyis by Dr. RFarhat et al, tacrolimus whole blood levels decrease in the 1st & 2nd trimesters then increase back to pre-pregnancy levels postpartum. Needs further studies to guide dose adjustment. @RheumNow #ACR24 abs1535 https://t.co/5MovzPJoFc

Links:

sheila RHEUMarampa ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×